BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 35197058)

  • 1. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. circATAD2 mitigates CD8
    Zhang Z; Huo W; Li J
    Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
    Fu W; Liu L; Tong S
    Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
    Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
    J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer.
    Zhou S; Sheng L; Zhang L; Zhang J; Wang L
    Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130542. PubMed ID: 38103759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
    Wang H; Tang A; Cui Y; Gong H; Li H
    Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m
    Long Y; Song D; Xiao L; Xiang Y; Li D; Sun X; Hong X; Hou FF; Fu H; Liu Y
    Int J Biol Sci; 2024; 20(8):3185-3200. PubMed ID: 38904026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Guan H; Tian K; Luo W; Li M
    Cell Death Dis; 2023 Feb; 14(2):120. PubMed ID: 36781839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyltransferase-like 3 induces the development of cervical cancer by enhancing insulin-like growth factor 2 mRNA-binding proteins 3-mediated apoptotic chromatin condensation inducer 1 mRNA stability.
    Su C; Zhang Y; Chen P; Yang W; Du J; Zhang D
    Bioengineered; 2022 Mar; 13(3):7034-7048. PubMed ID: 35255776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
    Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
    J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
    Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
    J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
    Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.